CDK1 and prostate carcinoma: Liu et al. [74] have shown that sodium metavanadate (36) caused G2/M cell cycle arrest in prostate cancer cells, which is evidenced by the increase in the level of phosphorylated cdc2(cdk1) at its inactive Tyr-15 site.